Data

ALLG NHL26 A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive

Health Data Australia Contributor Records
Trotman, Judith ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/0219-PB05&rft.title=ALLG NHL26 A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive&rft.identifier=http://doi.org/10.58109/0219-PB05&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: - data for 37 patients with relapsed follicular lymphoma - PET response of all 37 registered patients at screening, 6 months post study treatment, and at disease progression - QoL data for all patients up to 18 months of follow-up - 2 years of Rituximab and Lenolidomide treatment data - Follow-up treatment data for all patients up to 18months - Comparison of treatment arm data for conversion of PET+ to PET - Progression Free Survival and Overall survival data &rft.creator=Trotman, Judith &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12613000106730&rft_subject=Chemotherapy&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

"Dataset includes: - data for 37 patients with relapsed follicular lymphoma - PET response of all 37 registered patients at screening, 6 months post study treatment, and at disease progression - QoL data for all patients up to 18 months of follow-up - 2 years of Rituximab and Lenolidomide treatment data - Follow-up treatment data for all patients up to 18months - Comparison of treatment arm data for conversion of PET+ to PET - Progression Free Survival and Overall survival data "

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
Chemotherapy |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

doi : https://doi.org/10.1182/blood-2021-146343

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers
Similar data you may be interested in: